Key Takeaways:
Danuo Pharmaceuticals, a biotechnology company founded in 2013, has passed its listing hearing with the Hong Kong Stock Exchange for an initial public offering under Chapter 18A, which accommodates pre-revenue biotech firms.
The application was filed with joint sponsorship from CITIC Securities and ABCI. "Passing the hearing moves the company a significant step closer to its public market debut," a person familiar with the matter said, though the exact timeline and deal size were not yet disclosed.
According to its post-hearing information pack, the near-commercialization stage company has built a pipeline of seven innovative programs. The two core assets include rifotnilazole (TNP-2198), a candidate drug for treating Helicobacter pylori infection, and riforquinolone (TNP-2092 injection), a therapy for implant-associated bacterial infections.
The successful hearing for Danuo Pharmaceuticals could signal renewed investor interest in the biotech sector on the Hong Kong exchange. The performance of its IPO, once priced and listed, will be a key test of market appetite for pre-revenue medical technology companies in the current economic climate. Investors will be watching for the release of the official prospectus, which will detail the offer price and use of proceeds.
This article is for informational purposes only and does not constitute investment advice.
